Related Experiment Video
Updated: Sep 1, 2025
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now
Jenny Peng1, Srikala Sridhar1, Arlene Odelia Siefker-Radtke2
1Division of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, 7-613, 700 University Avenue, Toronto, ON, M5G 2C1, Canada.
Opinion Statement:
As we come to better understand cancer genomics, we are increasingly shifting towards precision medicine. FGFR has been elucidated as one of the oncogenic driver pathways in urothelial carcinoma, leading to exciting targeted drug development. Although many agents are being investigated, erdafitinib is the only FGFR inhibitor currently approved by the FDA for treating platinum-refractory metastatic urothelial carcinoma harboring susceptible FGFR2/3 alterations, with seemingly higher response rates than second-line chemotherapy or immunotherapy. In this review, we summarize the clinical data supporting FGFR inhibition, ways to optimize its use in routine clinical practice including FGFR testing, dosing, and toxicity management. We also highlight ongoing efforts evaluating combination strategies and testing in earlier treatment settings to further expand this targeted therapeutic approach in urothelial carcinoma.
Insights
Precision medicine advances cancer treatment. Erdafitinib offers a targeted therapy for urothelial carcinoma with FGFR alterations, showing promising results and guiding future treatment strategies.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Cancer genomics research is driving a shift towards precision medicine.
- Fibroblast Growth Factor Receptor (FGFR) is an oncogenic driver pathway in urothelial carcinoma.
- Targeted drug development for FGFR alterations is a key area of research.
Purpose of the Study:
- To review clinical data supporting FGFR inhibition in urothelial carcinoma.
- To provide guidance on optimizing erdafitinib use in clinical practice.
- To highlight future directions for FGFR-targeted therapies.
Main Methods:
- Review of clinical data on FGFR inhibitors, focusing on erdafitinib.
- Discussion of FGFR testing, dosing strategies, and toxicity management.
- Exploration of combination strategies and earlier treatment settings.
Main Results:
- Erdafitinib is the sole FDA-approved FGFR inhibitor for platinum-refractory metastatic urothelial carcinoma with susceptible FGFR2/3 alterations.
- Erdafitinib demonstrates potentially higher response rates compared to standard second-line treatments.
- Ongoing research is exploring expanded use in earlier settings and combination therapies.
Conclusions:
- FGFR inhibition represents a significant advancement in precision oncology for urothelial carcinoma.
- Optimizing erdafitinib's clinical application requires careful patient selection, dosing, and toxicity management.
- Future research aims to broaden the application of FGFR-targeted therapies in urothelial carcinoma.
More Related Videos
09:28Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle